New Scientific News

Indian Journal of Cancer

SoMex Research and Health Organization assessed the data collection in Immunotherapy in Lung Cancer at BMCHRC.

6 MAJOR ASCO UPDATE HIGHLIGHTS

• OVERALL SURVIVAL DATE of PALBOCICLIB presented (TRIO-18) in first line setting.
• Benefit of wonder drug DACOMITINIB over GEFATINIB in treatment of advance EGFR positive non small cell lung cancer.
• Positive outcome of phase 3 data of trastuzamab with palbociclib.
• First line usage of pfizer and e.merck immuno oncology product avelumab plus axitinib.
• Successful phase 3 trial results of SUTENT in adjuvent setting.
• Efficacy and safety of lorlatinib in ALK positive lung cancer over Crizotinib ceritinib and alectinib.